30/07/2015 21:05:33 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
07/30/20158:00AMPRNUSCelebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabete...
Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal Chef Leticia Visits Fiesta del Sol in Chicago on July 31 with Desafiando La Diabetes: Logra Tus Metas Program PR Newswire KENILWORTH, N.J., July 30, 2015 KENILWORTH, N.J... More...>>
07/28/20155:00PMDJNGilead Sales Soar on Hepatitis Drugs
Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected sales of the newer Harvoni. For the year, the company again raised its guidance for net product sales, this time by $1... More...>>
07/28/20154:15PMBWPamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Pamela J. Craig, retired chief financial officer of Accenture, and Dr. Paul B. Rothman, dean of the medical faculty, vice president for medicine of The Johns Hopkins University and chief executive officer of Johns Hopkins Medicine... More...>>
07/28/201512:26PMDJNMerck Earnings Hurt by Arthritis Drug Knockoffs
By Peter Loftus Low-cost knockoffs of the arthritis treatment Remicade in Europe hurt Merck & Co.'s second-quarter sales and earnings, a harbinger of the pressure facing sellers of other costly biotechnology drugs in the coming years. Merck, which handles Remicade marketing in Europe, said the company's sales of the... More...>>
07/28/20158:23AMDJNMerck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker--Update
By Angela Chen Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second... More...>>
07/28/20158:20AMDJNMerck Earnings Top Views Amid Cost Cuts
Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second quarter, hurt... More...>>
07/28/20158:12AMDJNMerck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker
By Angela Chen Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second... More...>>
07/28/20157:00AMBWMerck Announces Second-Quarter 2015 Financial Results
Second-Quarter 2015 Non-GAAP EPS of $0.86, Excluding Certain Items; GAAP EPS of $0.24 Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.52 to $1.71 Second-Quarter 2015 Worldwide Sales Were $9.8 Billion, a Decrease of 11... More...>>
07/28/20156:45AMBWMerck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and cCAM Biotherapeutics announced today that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies... More...>>
07/28/20156:30AMBWMerck Announces U.S. Food & Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigation...
Company Granted FDA Priority Review with Target Action Date of January 28, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for grazoprevir/elbasvir (100mg/50mg), an investigational... More...>>
07/27/20158:30AMBWMerck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA™ (Ceftolozane and Tazobactam)
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic ZERBAXA™ (ceftolozane and tazobactam) for the... More...>>
07/23/20159:27PMBWMSD annonce que l’Agence européenne du médicament a accepté la demande d’autorisation de mise sur le marché pour le g...
MSD, connue sous l’appellation Merck (NYSE : MRK) aux États-Unis et au Canada, a annoncé aujourd’hui que l’Agence européenne du médicament (EMA) avait accepté, à des fins d’examen, une demande d’autorisation de mise sur le marché (MAA) pour le grazoprevir/elbasvir (100 mg/50 mg), un traitement associé... More...>>
07/23/20157:10PMBWMSD annuncia l'accettazione da parte dell'Agenzia Europea dei Medicinali (European Medicines Agency, EMA) della domanda di au...
MSD annuncia l'accettazione da parte dell'Agenzia Europea dei Medicinali (European Medicines Agency, EMA) della domanda di autorizzazione per l'immissione in commercio di Grazoprevir/Elbasvir, una terapia sperimentale per il trattamento dell'infezione cronica da virus dell'epatite C MSD, nota negli Stati Uniti e in Canada... More...>>
07/23/20157:06PMBWMSD meldet Annahme des Zulassungsantrags für Grazoprevir/Elbasvir, einem Prüfpräparat zur Behandlung von chronischen Hepat...
MSD, in den Vereinigten Staaten und Kanada bekannt unter dem Namen Merck (NYSE:MRK), meldete heute, dass die Europäische Arzneimittelagentur (EMA) einen Zulassungsantrag (Marketing Authorisation Application, MAA) für Grazoprevir/Elbasvir (100 mg/50 mg) zur Prüfung angenommen hat. Dabei handelt es sich um ein in der... More...>>
07/23/20151:35PMDJNBristol-Myers Revenue Boosted by Cancer Drug Opdivo
By Jonathan D. Rockoff and Tess Stynes Bristol-Myers Squibb Co. said Thursday its second-quarter revenue rose 7% thanks to a boost from sales of its new Opdivo cancer drug, results indicating the company's big bet on such immunotherapies is paying off. For years, researchers struggled to figure out how to enlist the body's... More...>>
07/23/201511:02AMBWMSD Announces European Medicines Agency Acceptance of Marketing Authorisation Application for Grazoprevir/Elbasvir, an Invest...
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorisation application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy, for the treatment of adult patients... More...>>
07/23/201511:02AMBWMerck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Inve...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult... More...>>
07/22/20151:28PMBWMerck Announces Fourth-Quarter 2015 Dividend
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the company’s common stock for the fourth quarter of 2015. Payment will be made on October 7, 2015, to shareholders of record at the close of business... More...>>
07/22/20157:00AMBWEuropean Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line & Previously-treate...
KEYTRUDA Demonstrated Superior Survival versus Ipilimumab in a Phase 3 Clinical Trial Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of advanced (unresectable... More...>>
07/22/20157:00AMBWEuropäische Kommission erteilt Anti-PD-1-Therapie KEYTRUDA® (Pembrolizumab) von MSD die Zulassung zur Behandlung von Erstli...
Pembrolizumab zeigt im Rahmen einer klinischen Phase-III-Studie verbessertes Gesamtüberleben im Vergleich mit Ipilimumab MSD, in den Vereinigten Staaten und Kanada bekannt unter dem Namen Merck, meldete heute, dass die Europäische Kommission die Zulassung für KEYTRUDA® (Pembrolizumab), die Anti-PD-1-Therapie des Unternehmens... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150730 21:05